About a year ago, the EU directive on combating counterfeit medicines (2011/62 / EU) came into effect. Until 2 January 2013, the Member States have time to adapt their national legislation accordingly. For the pharmaceutical companies, the implementation of the Directive will bring some challenges. For 2015, the pharmaceutical production throughout Europe is to be consistently serialized. Each product will get a serial number to make tracking and tracing of medicinal products possible. What has to be considered and what methods are there to protest the manipulation - revealed the experts, Dr. Stephan Rau, a lawyer and partner at McDermott Will & Emery and Kurt Hoppen, Executive Vice President of Bluhm Systeme GmbH.